Multiplexed Protease Activity Assay for Low-Volume Clinical Samples Using Droplet-Based Microfluidics and Its Application to Endometriosis

Chia‐Hung Chen, Chia-Hung Chen, Miles A. Miller, Aniruddh Sarkar, Michael T. Beste, Beste MT, Keith B Isaacson, Keith Isaacson, Isaacson KB, Douglas A. Lauffenburger, Lauffenburger DA, Linda G. Griffith, Jongyoon Han, Han J
Journal of the American Chemical Society · 2012 · vol. 135(5) , pp. 1645–1648 · doi:10.1021/ja307866z · PMID:23157326 · PMC3566300 · W2070168562
article OA: green CC0 ⤵ 7 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This paper details a droplet-based microfluidic method to measure multiple protease activities in small clinical samples, demonstrating decreased MMP-2 and ADAM-9 activity in endometriosis patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

As principal degrading enzymes of the extracellular matrix, metalloproteinases (MPs) contribute to various pathologies and represent a family of promising drug targets and biomarker candidates. However, multiple proteases and endogenous inhibitors interact to govern MP activity, often leading to highly context-dependent protease function that unfortunately has impeded associated clinical utility. We present a method for rapidly assessing the activity of multiple specific proteases in small volumes (<20 μL) of complex biological fluids such as clinical samples that are available only in very limited amounts. It uses a droplet-based microfluidic platform that injects the sample into thousands of picoliter-scale droplets from a barcoded droplet library (DL) containing mixtures of unique, moderately selective FRET-based protease substrates and specific inhibitors and monitors hundreds of the reactions thus initiated simultaneously by tracking these droplets. Specific protease activities in the sample are then inferred from the reaction rates using a deconvolution technique, proteolytic activity matrix analysis (PrAMA). Using a nine-member DL with three inhibitors and four FRET substrates, we applied the method to the peritoneal fluid of subjects with and without the invasive disease endometriosis. The results showed clear and physiologically relevant differences with disease, in particular, decreased MMP-2 and ADAM-9 activities.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Enzyme Assays Metalloproteases Microfluidic Analytical Techniques Endometriosis Endometriosis Female Fluorescence Resonance Energy Transfer Humans Metalloproteases Metalloproteases Metalloproteases Particle Size Protease Inhibitors Protease Inhibitors Substrate Specificity Surface Properties

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Cited by (7)

Source provenance

europepmc
last seen: 2026-08-28T06:11:01.063540+00:00
openalex
last seen: 2026-05-11T03:49:50.569207+00:00
pubmed
last seen: 2026-05-13T22:15:58.344756+00:00
License: CC0 · commercial use OK